Susie Ro
Neurology · Evanston, ILNPI 1902965643
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,541 of the $6,486 with a category attached, or 70.0%. 27 manufacturers reported payments, led by Boston Scientific at 45.8% of the total. 2025 is the largest year on record at $2,724, more than ten times the $66 reported in 2022.
Across 160 payments — averaging $40.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- AbbVie$865
- Teva Pharmaceuticals USA, Inc.$361
- Merz Pharmaceuticals, LLC$256
- Eisai Inc.$222
- Lilly USA, LLC$218
- plus $2K from 21 others
Across 15 payments — averaging $2368.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$14K
- Sunovion Pharmaceuticals Inc.$11K
- Insightec,ltd$10K
What the payments were for
- Travel & lodging$1,92030%
- Food & beverage$4,54170%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 22 | $2,969 |
| AbbVie | 36 | $865 |
| Teva Pharmaceuticals USA, Inc. | 19 | $361 |
| Merz Pharmaceuticals, LLC | 6 | $256 |
| Eisai Inc. | 8 | $222 |
| Lilly USA, LLC | 9 | $218 |
| Pfizer | 9 | $195 |
| Novo Nordisk | 2 | $187 |
| Ipsen Biopharmaceuticals, Inc | 6 | $186 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $154 |
| Lundbeck LLC | 5 | $149 |
| Acadia Pharmaceuticals Inc | 5 | $121 |
| Neurocrine Biosciences, Inc. | 4 | $91 |
| Biogen | 3 | $71 |
| Medtronic | 3 | $62 |
| Kyowa Kirin, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| MDD US Operations, LLC | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 1 | $34 |
| Impel Pharmaceuticals Inc. | 1 | $31 |
| Amneal Pharmaceuticals LLC | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Acorda Therapeutics, Inc | 1 | $25 |
| Galderma Laboratories, L.p. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Revance Therapeutics, Inc. | 1 | $18 |
| Cala Health, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,061
- XEOMIN$109
- BIONIC NAVIGATOR$109
How this compares
$6,486 in reported general payments places this provider in the 75th percentile of 790 neurology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 13 | $83,366 |
| UbrelvyUbrogepant | 40 | $63,822 |
| RytaryCarbidopa/Levodopa | 47 | $45,471 |
| QuliptaAtogepant | 33 | $35,636 |
| Nurtec OdtRimegepant Sulfate | 30 | $33,686 |
| Emgality PenGalcanezumab-Gnlm | 30 | $26,010 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $11,666 |
| Rivastigmine | 44 | $6,013 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 199 | $5,066 |
| Rasagiline Mesylate | 35 | $4,102 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 42 | $1,433 |
| Memantine Hcl ErMemantine Hcl | 18 | $916 |
| Gabapentin | 45 | $685 |
| Ropinirole Hcl | 32 | $547 |
| Primidone | 19 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $865 | $99,45873 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $361 | $83,36613 claims |
| Amneal Pharmaceuticals LLCRytary | $28 | $45,47147 claims |
| PfizerNurtec Odt | $195 | $33,68630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 790 neurology providers in Illinois.
Other neurology in Evanston
- James VociEvanston$345K
- Afif HentatiEvanston$189K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.